Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
SAN DIEGO, Nov. 20, 2023 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1×1 investor meetings at the 35th Annual Piper Sandler Healthcare Conference, which is taking place at the Lotte New York Palace in New York from November 28-30, 2023.
Related news for (CRDF)
- Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
- Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
- 24/7 Market News Snapshot 29 July, 2025 – Cardiff Oncology, Inc. Common Stock (NASDAQ:CRDF)
- 24/7 Market News Snapshot 29 July, 2025 – Cardiff Oncology, Inc. Common Stock (NASDAQ:CRDF)
- Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC